Torigen Pharmaceutical is a commercial-stage animal health biologics company that aims to innovate pet cancer treatment by leveraging the pet’s immune system to create personalized cancer immunotherapies. Led by CEO Ashley Kalinauskas, the company is a spin-out from the University of Notre Dame and is based in Farmington, CT. Torigen is focused on developing new biologic products to treat cancer in companion animals. The company says it will use the proceeds from its latest financing to continue to develop new products and expand its salesforce. The company is described as commercial-stage. The recent financing provides additional capital to support its product development and commercial expansion.

Total raised

$13M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022